DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting of the Board of Scientific Counselors, NIDA.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended, for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute on Drug Abuse, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, NIDA.

Date: December 3–4, 2018.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators.

Place: Intramural Research Program, National Institute on Drug Abuse, NIH, Johns Hopkins Bayview Campus, Baltimore, MD 21223.

Contact Person: Joshua Kysiak, Program Specialist, Biomedical Research Center, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, 251 Bayview Boulevard, Baltimore, MD 21224, 443–740–2465, kysiakjo@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHSS)


Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018–24099 Filed 11–2–18; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.


Date: November 16, 2018.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate cooperative agreement applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301–827–5819, gml45@nih.gov.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel II Interview: NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1).

Date: December 10, 2018.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301–827–5820, hiromi.ono@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHSS)


Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018–24101 Filed 11–2–18; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.


Date: November 28, 2018.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Abdelouahab Aitouche, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4222, MSC 7814, Bethesda, MD 20892, 301–435–2365, aitouchea@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Cancer Health Disparities.

Date: November 29–30, 2018.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.


Contact Person: Reigh-Yi Lin, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–827–6009, lin.reigh-yi@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Cancer Health Disparities.

Date: November 29–30, 2018.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.


Contact Person: Ola Mae Zack Howard, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4192, MSC 7806, Bethesda, MD 20892, 301–451–4467, howardz@mail.nih.gov.


Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018–24103 Filed 11–2–18; 8:45 am]
ACTION: Notice for public comment.

SUMMARY: The Office of the Director, National Institutes of Health (NIH), on behalf of the National Science and Technology Council (NSTC); Committee on Science; Fast Track Action Committee on Health Science and Technology Response to the Opioid Crisis (Opioid FTAC), is requesting input on the content of a draft report, “Health Research and Development to Stem the Opioid Crisis: A Federal Roadmap.”

DATES: Comments must be submitted on or before December 5, 2018.

ADDRESSES: You may submit comments by email to opioidsroadmap@OSTP.eop.gov. Please include “Health Research and Development to Stem the Opioid Crisis: A Federal Roadmap” in the subject line of the message.

Instructions: The draft report is available for download at: https://www.nih.gov/draft-ftac. Response to this Notice for Public Comment is voluntary. Clearly indicate the section and page number, if applicable, to which submitted comments pertain. All submissions must be in English. Please clearly label submissions as regarding “Health Research and Development to Stem the Opioid Crisis: A Federal Roadmap.” When the final report is issued, relevant comments and the commenters’ names, along with the commenters’ responses, may become part of the public record and be made available to view online. NIH therefore requests that commenters do not submit business proprietary information, copyrighted information, or personally identifiable information in response to this Notice for Public Comment. Please note that the U.S. Government will not pay for response preparation or for the use of any information contained in the response.

FOR FURTHER INFORMATION CONTACT: Sara Brenner, Office of Science and Technology Policy, (202) 456-444, or opioidsroadmap@ostp.eop.gov.

SUPPLEMENTARY INFORMATION: The Opioid FTAC was chartered in December 2017 to facilitate coordination of health Research and Development (R&D) and related Science and Technology (S&T) activities across agencies, and with other Administration initiatives, in support of the national response to the opioid crisis; facilitate interagency sharing of opioid-related health R&D findings, standard-based data and tools, and best practices; assess gaps in, and opportunities for strengthening R&D and related S&T response to the opioid crisis; and, identify opportunities to expedite promising and potentially groundbreaking R&D efforts to rapidly combat the crisis.

The draft report builds on the recommendations in the report from the President’s Commission on Combating Drug Addiction and The Opioid Crisis, as well as recommendations from multiple other sources, such as the National Academy of Sciences report on Pain Management and the Opioid Epidemic, the Interagency Pain Research Coordinating Committee’s Federal Pain Research Strategy, the National Governors Association report on Governor’s Recommendations for Federal Action to End the Nation’s Opioid Crisis, and the Surgeon General’s report Facing Addiction in America, among others, to identify research and development opportunities to coordinate the Federal Government’s S&T response to the opioid crisis. This notice solicits relevant public input on the draft report.

The report describes:
- Seven areas of R&D: (1) The Biology and Chemistry of Opioid Addiction and Pain, (2) Non-Biological Contributors to Opioid Addiction, (3) Management, (4) Prevention of Opioid Addiction, (5) Treatment of Opioid Addiction and Withdrawal, (6) Overdose Prevention and Recovery, and (7) Community Consequences of Opioid Addiction;
- Research recommendations generated by the Opioid FTAC in each of these areas;
- An eighth section that includes recommendations on ways to enhance Federal interagency coordination as well as coordination with non-Federal stakeholders.

Lawrence A. Tabak,
Deputy Director, National Institutes of Health.